LncRNA SNHG6 Promotes G1/S-phase Transition in Hepatocellular Carcinoma by Impairing MiR-204-5p-mediated Inhibition of E2F1

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2021 Apr 7

PMID 33824472

Citations 14

Authors

Kai Chen

Yifu Hou

Rui Liao

Youzan Li

Hongji Yang

Jun Gong

Affiliations

Soon will be listed here.

Abstract

Emerging evidence suggests that long noncoding RNAs (lncRNAs) function as competitive endogenous RNA (ceRNA) targeting proteins and genes; however, the role of lncRNAs in hepatocellular carcinoma (HCC) is not well understood. We investigated the mechanism by which lncRNA SNHG6 promotes the development of HCC. RT-qPCR revealed upregulated lncRNA SNHG6 in the HCC setting. Elevated SNHG6 expression was indicative of poor prognosis in patients with HCC. SNHG6 overexpression resulted in increased cyclin D1, cyclin E1, and E2F1 expression both in vitro and in vivo. SNHG6 also promoted HCC cell proliferation by enhancing G1-S phase transition in vitro. Dual luciferase reporter assays, RIP, and RNA pull-down assays demonstrated SNHG6 competitively bound to miR-204-5p and inhibited its expression preventing miR-204-5p from targeting E2F1. Overexpression of miR-204-5p abolished the effect of SNHG6. Our data suggest that SNHG6 functions as a ceRNA that targets miR-204-5p resulting in an increased E2F1 expression and enhanced G1-S phase transition, thereby promoting the tumorigenesis of HCC.

Citing Articles

Deciphering the nexus between long non-coding RNAs and endoplasmic reticulum stress in hepatocellular carcinoma: biomarker discovery and therapeutic horizons.

Goyal H, Parwani S, Kaur J Cell Death Discov. 2024; 10(1):451.

PMID: 39448589 PMC: 11502918. DOI: 10.1038/s41420-024-02200-2.

Role of MicroRNA-204 in Regulating the Hallmarks of Breast Cancer: An Update.

Bermudez M, Martinez-Barajas M, Bueno-Urquiza L, Lopez-Gutierrez J, Villegas-Mercado C, Lopez-Camarillo C Cancers (Basel). 2024; 16(16).

PMID: 39199587 PMC: 11352763. DOI: 10.3390/cancers16162814.

Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy.

Huang P, Wen F, Li Q Front Pharmacol. 2024; 15:1432490.

PMID: 39119602 PMC: 11306149. DOI: 10.3389/fphar.2024.1432490.

MicroRNA-204-5p Inhibits Hepatocellular Carcinoma by Targeting the Regulator of G Protein Signaling 20.

Su Y, Lu Y, An H, Liu J, Ye F, Shen J ACS Pharmacol Transl Sci. 2023; 6(12):1817-1828.

PMID: 38093845 PMC: 10714421. DOI: 10.1021/acsptsci.3c00114.

Lnc-SNHG5 Promoted Hepatocellular Carcinoma Progression Through the RPS3-NFκB Pathway.

Hao J, Liu Y, Guo F, Fu G, Ning J, Ruan X Int J Gen Med. 2023; 16:5651-5664.

PMID: 38059157 PMC: 10697148. DOI: 10.2147/IJGM.S442937.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Greten T, Lai C, Li G, Staveley-OCarroll K . Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):510-524. PMC: 6340758. DOI: 10.1053/j.gastro.2018.09.051. View

Boon R, Jae N, Holdt L, Dimmeler S . Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets?. J Am Coll Cardiol. 2016; 67(10):1214-1226. DOI: 10.1016/j.jacc.2015.12.051. View

Wong C, Tsang F, Ng I . Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018; 15(3):137-151. DOI: 10.1038/nrgastro.2017.169. View

Huang Z, Zhou J, Peng Y, He W, Huang C . The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. PMC: 7161154. DOI: 10.1186/s12943-020-01188-4. View

Yuan S, Zhang J, Xu Q, Yang Y, Zhou W . Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma. Cancer Lett. 2015; 379(2):239-44. DOI: 10.1016/j.canlet.2015.08.008. View

Birgani M, Hajjari M, Shahrisa A, Khoshnevisan A, Shoja Z, Motahari P . Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma. Pathol Oncol Res. 2017; 24(2):329-337. DOI: 10.1007/s12253-017-0241-3. View

10.

Wu G, Ju X, Wang Y, Li Z, Gan X . Up-regulation of activates expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression. Cell Cycle. 2019; 18(16):1849-1867. PMC: 6681790. DOI: 10.1080/15384101.2019.1629772. View

11.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

12.

Cao C, Zhang T, Zhang D, Xie L, Zou X, Lei L . The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene. 2016; 36(8):1112-1122. DOI: 10.1038/onc.2016.278. View

13.

Otto T, Sicinski P . Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017; 17(2):93-115. PMC: 5345933. DOI: 10.1038/nrc.2016.138. View

14.

Ingham M, Schwartz G . Cell-Cycle Therapeutics Come of Age. J Clin Oncol. 2017; 35(25):2949-2959. PMC: 6075824. DOI: 10.1200/JCO.2016.69.0032. View

15.

Zhang Y, Song X, Herrup K . Context-Dependent Functions of E2F1: Cell Cycle, Cell Death, and DNA Damage Repair in Cortical Neurons. Mol Neurobiol. 2020; 57(5):2377-2390. DOI: 10.1007/s12035-020-01887-5. View

16.

Gu Y, Wang X, Liu H, Li G, Yu W, Ma Q . SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncol Rep. 2018; 40(4):1863-1874. PMC: 6111541. DOI: 10.3892/or.2018.6621. View

17.

Farra R, Dapas B, Baiz D, Tonon F, Chiaretti S, Del Sal G . Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells. Biochimie. 2015; 112:85-95. DOI: 10.1016/j.biochi.2015.02.015. View

18.

Zhao H, Zhang Y, Sun J, Zhan C, Zhao L . Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016; 23(5):237-48. PMC: 7838684. DOI: 10.3727/096504016X14562725373671. View

19.

Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y . Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem. 2013; 288(20):14510-14521. PMC: 3656305. DOI: 10.1074/jbc.M113.458737. View

20.

Duan Y, Tian L, Gao Q, Liang L, Zhang W, Yang Y . Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget. 2016; 7(29):45863-45875. PMC: 5216766. DOI: 10.18632/oncotarget.10244. View